Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Fjarde AP Fonden Fourth Swedish National Pension Fund

Fjarde AP Fonden Fourth Swedish National Pension Fund raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 21.6% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 67,623 shares of the company’s stock after purchasing an additional 12,000 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Neurocrine Biosciences were worth $7,479,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. GeoWealth Management LLC raised its position in shares of Neurocrine Biosciences by 65.4% during the 4th quarter. GeoWealth Management LLC now owns 258 shares of the company’s stock valued at $35,000 after acquiring an additional 102 shares in the last quarter. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Neurocrine Biosciences during the 1st quarter valued at approximately $34,000. Golden State Wealth Management LLC raised its position in shares of Neurocrine Biosciences by 116.9% during the 1st quarter. Golden State Wealth Management LLC now owns 397 shares of the company’s stock valued at $44,000 after acquiring an additional 214 shares in the last quarter. Versant Capital Management Inc raised its position in shares of Neurocrine Biosciences by 404.9% during the 1st quarter. Versant Capital Management Inc now owns 409 shares of the company’s stock valued at $45,000 after acquiring an additional 328 shares in the last quarter. Finally, Harbor Capital Advisors Inc. acquired a new stake in shares of Neurocrine Biosciences during the 1st quarter valued at approximately $48,000. 92.59% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on NBIX. Royal Bank Of Canada dropped their price target on Neurocrine Biosciences from $146.00 to $144.00 and set an “outperform” rating on the stock in a research report on Thursday, July 31st. HC Wainwright lowered their price objective on Neurocrine Biosciences from $185.00 to $168.00 and set a “buy” rating for the company in a research note on Tuesday, April 22nd. Piper Sandler upped their price objective on Neurocrine Biosciences from $154.00 to $175.00 and gave the stock an “overweight” rating in a research note on Thursday, July 31st. Needham & Company LLC upped their price objective on Neurocrine Biosciences from $138.00 to $139.00 and gave the stock a “buy” rating in a research note on Tuesday, May 6th. Finally, JPMorgan Chase & Co. upped their price objective on Neurocrine Biosciences from $140.00 to $145.00 and gave the stock a “neutral” rating in a research note on Thursday, July 31st. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $160.90.

Neurocrine Biosciences Stock Up 1.2%

Shares of NBIX stock opened at $132.90 on Friday. Neurocrine Biosciences, Inc. has a fifty-two week low of $84.23 and a fifty-two week high of $154.87. The stock has a market capitalization of $13.18 billion, a P/E ratio of 39.32, a P/E/G ratio of 0.95 and a beta of 0.25. The stock has a 50-day simple moving average of $129.21 and a 200 day simple moving average of $119.83.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Wednesday, July 30th. The company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.98 by $0.08. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%. The business had revenue of $687.50 million during the quarter, compared to the consensus estimate of $653.09 million. During the same period in the prior year, the business posted $1.63 earnings per share. Neurocrine Biosciences’s revenue was up 16.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Insider Activity

In other news, Director Kevin Charles Gorman sold 106,322 shares of the company’s stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $126.41, for a total transaction of $13,440,164.02. Following the completion of the sale, the director directly owned 514,596 shares of the company’s stock, valued at $65,050,080.36. This represents a 17.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Ingrid Delaet sold 457 shares of the company’s stock in a transaction on Thursday, July 10th. The shares were sold at an average price of $135.00, for a total value of $61,695.00. Following the sale, the insider directly owned 4,730 shares of the company’s stock, valued at approximately $638,550. This represents a 8.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 196,573 shares of company stock valued at $25,112,766 over the last three months. Insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.